anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
There is a paucity of research on the experiences of parents of children with trisomy X (47,XXX). Increased prenatal diagnoses associated with advances in noninvasive prenatal screening necessitate a better understanding of how trisomy X impacts family systems. This qualitative investigation aimed to describe the lived experience of parents of young daughters with prenatally identified trisomy X to guide genetic counseling. Semi-structured qualitative interviews were conducted via teleconferencing with parents (n = 11) of girls with trisomy X, ages 6-44 months. A descriptive phenomenological approach was used to code transcripts for significant statements and reduce data into themes describing the experience of receiving a diagnosis of trisomy X and the experience of early parenting in this population. Participants described an emotional journey of adapting to prenatally identified trisomy X. Four descriptive themes included two related, yet distinct, life stages: Negative Diagnostic Experience and a Hopeful Early Childhood, as well as two ongoing experiences: Persistent Ambiguity and Coping with and Adapting to Uncertainty. Results suggest providers should carefully consider word choice and timing in delivery of diagnosis, and genetic counseling should provide expectant parents with current research specific to trisomy X, facilitate connections with other parents of young girls with trisomy X, introduce developmental monitoring approaches, and be prepared to support families with a range of emotional responses to the diagnosis and decisions regarding disclosure.
The invention relates to the method of preparation and modification of a hyaluronan derivative with an aldehydic group in the position (6) of the polysaccharide glucosamine part. The oxidation of the hyaluronic acid can be performed by means of Dess-Martin periodinane (DMP) agent. The prepared aldehyde can be used for binding amine, diamine, amino acid, peptide and other compounds containing an amino group, e.g. by means of the reductive amination with NaBH 3 CN in water or in a water-organic solvent system. When a diamine or compounds containing three or more amino groups are used, cross-linked hyaluronan derivatives can be prepared. Cross-linked derivatives can also be prepared by the reaction of the aldehyde with a hyaluronan substituted by an amino-alkyl group HA-alkyl-NH 2 .
The loss of E-cadherin, an epithelial cell adhesion molecule, has been implicated in metastasis by mediating the epithelial-mesenchymal transition, which promotes invasion and migration of cancer cells. However, recent studies have demonstrated that E-cadherin supports the survival and proliferation of metastatic cancer cells. Here, we identified a metabolic role for E-cadherin in breast cancer by upregulating the de novo serine synthesis pathway (SSP). The upregulated SSP provided metabolic precursors for biosynthesis and resistance to oxidative stress, enabling E-cadherin+ breast cancer cells to achieve faster tumor growth and enhanced metastases. Inhibition of phosphoglycerate dehydrogenase, a rate-limiting enzyme in the SSP, significantly and specifically hampered proliferation of E-cadherin+ breast cancer cells and rendered them vulnerable to oxidative stress, inhibiting their metastatic potential. These findings reveal that E-cadherin reprograms cellular metabolism, promoting tumor growth and metastasis of breast cancers. Significance: E-Cadherin promotes the progression and metastasis of breast cancer by upregulating the de novo serine synthesis pathway, offering promising targets for inhibiting tumor growth and metastasis in E-cadherin-expressing tumors.
PURPOSE:The titled composition that contains an emulsifier mixture composed of a salt from a higher fatty acid and an inorganic base, an alpha-monoglycerol ether and a nonionic surfactant, thus showing high emulsion stability, stability with time and usability and being safe to human bodies. CONSTITUTION:The objective composition is composed of (A) a salt from a higher fatty acid and an inorganic base, (B) an alpha-monoglycerol ether of the formula: CH2OH.CHOH.CH2OR (R is residue of saturated aliphatic alcohol of 16 or more carbon atoms) and (C) a nonionic surfactant other than component (B). The composition is liquid or water-based and used for cosmetics. The addition of the resultant emulsifier inhibits the crystallization of the fatty acid even when it is low viscosity and stabilizes changes in emulsion, odor and color, with time. Further, it is safe to human bodies and shows luster on the surface, thus being used in wide application of cosmetics. An example of component (B) is cetyl alpha-monogycerol ether.
FIELD: veterinary science, microbiology. SUBSTANCE: probiotic preparation has the following components: dry bacterial mass of bifidobacteria, dry bacterial mass of streptococci, dry bacterial mass of recombinant strain of Bacillus subtilis producing human alpha- 2-interferon, carbohydrates, aluminium oxide, aluminium hydroxide and filling agent. Preparation can contain additionally dry bacterial mass of acidophilic bacteria also. The preparation composition can contain any strains of bifidobacteria, streptococci and lactic acid bacteria showing high adhesive ability and antagonistic activity. Also, any recombinant strains of Bacillus subtilis that are able to produce human alpha-2-interferon can be used. In part, the known strains of Bifidobacterium globosum VGNKI N BF-4-DEP, Streptococcus faecium VGNKI N 27-B- DER, Lactobacillus acidophilus VGNKI and industrial strain of Bacillus subtilis B-7092 can be used. Preparation diminishes time of animal treatment, enhances the level of natural resistance and stimulates immune processes. Invention is designated for preparing the biopreparation showing simultaneous antibacterial and antiviral activities that is able to enhance immune status of animal and poultry body and recover their normal intestinal microflora. EFFECT: enhanced effectiveness, improved properties of preparation. 5 cl, 2 tbl, 5 ex
TNFα antagonist compounds and methods of using the same are disclosed. The compounds comprise a molecular surface that is substantially similar to at least one molecular surface of human TNFα. The compounds bind to TNF receptors but do not produce the same biological effect as that which occurs when TNFα binds to a TNF receptor. Methods of inhibiting tumor necrosis factor activity are disclosed. The methods comprise the step of contacting tumor necrosis factor alpha with a TNFα antagonist. Methods of treating individuals suspected of suffering from or being susceptible to a disease or disorder mediated by tumor necrosis factor-alpha activity are disclosed. The methods comprise the step of administering to said individual a therapeutically effective amount of a TNFα antagonist.
Respiratory failure is characterized by the incapacity of the respiratory system to maintain the normal arterial blood gas homeostasis. Specifically, the overlap of hypoxaemia and hypercapnia (PaCO2 \>6 kPa) is referred to as Hypercapnic Respiratory Failure (HRF). HRF is one of the most common causes for hospital admission with high re-admission rates, therefore constitute a major burden on healthcare systems. Non Invasive Ventilation (NIV) is a well established treatment in patients with hypercapnic respiratory failure who frequently suffer with associated pulmonary hypertension (PH). NIV helps to increase arterial oxygenation and reduces hypercapnia. It is used in patients with hypercapnic respiratory failure caused by Obesity Hypoventilation Syndrome (OHS). The associated degree of PH can lead to an increased afterload of the right ventricle (RV) that causes progressive remodelling of the right heart. RV dysfunction is correlated with a reduced long term prognosis in respiratory conditions. In literature NIV is shown as effective method to treat acute hypercapnic respiratory failure in OHS.

It has not been described how NIV impacts on cardiac function and NRD in OHS.
The invention relates to an escherichia coli recombinant chicken alpha-gamma divalent interferon and a preparation method thereof. The invention aims at providing the interferon which has good anti-tumor effect and can improve immunity of livestock and poultry and realize control over diseases within a short time. The interferon comprises the components such as an escherichia coli recombinant chicken alpha-interferon and an escherichia coli recombinant chicken gamma-interferon; and the preparation method comprises the steps of gene design, construction of an expression vector, induction of expression, purification of a target protein and activity detection. The medicine is an alternative medicine for treating viral diseases of the livestock and the poultry, and escherichia coli is utilized for expressing the chicken alpha-interferon and the chicken gamma-interferon, thereby having a broad-spectrum antivirus role. The divalent interferon can have immunoregulation activity and a certain antivirus activity after purifying the protein, and the two interferons have obvious synergy when being combined and applied clinically. The divalent interferon prepared by the invention is better than any one interferon which is applied separately in the effects of treating and preventing newcastle disease and bursal disease.
The psychological treatment consists of 11 sessions (55 minutes per occasion), where the patient meets a psychologist face-to-face (either licensed or under training to be licensed) once a week. In between sessions, patients are supposed to complete homework exercises that are related to the contiguous sessions (2 x 45 minutes per week).
Urbanization with reduced microbial exposure is associated with an increased burden of asthma and atopic symptoms. Conversely, environmental exposure to endotoxins in childhood can protect against the development of allergies. Our study aimed to investigate whether the renaturation of the indoor environment with aerosolized radiation-detoxified lipopolysaccharide (RD-LPS) has a preventative effect against the development of ragweed-induced Th2-type airway inflammation. To explore this, cages of six-week-old BALB/c mice were treated daily with aerosolized native LPS (N-LPS) or RD-LPS. After a 10-week treatment period, mice were sensitized and challenged with ragweed pollen extract, and inflammatory cell infiltration into the airways was observed. As dendritic cells (DCs) play a crucial role in the polarization of T-cell responses, in our in vitro experiments, the effects of N-LPS and RD-LPS were compared on human monocyte-derived DCs (moDCs). Mice in RD-LPS-rich milieu developed significantly less allergic airway inflammation than mice in N-LPS-rich or common environments. The results of our in vitro experiments demonstrate that RD-LPS-exposed moDCs have a higher Th1-polarizing capacity than moDCs exposed to N-LPS. Consequently, we suppose that the aerosolized, non-toxic RD-LPS applied in early life for the renaturation of urban indoors may be suitable for the prevention of Th2-mediated allergies in childhood.
Somatic mutations and polymorphisms may play a role in multiple myeloma (MM) susceptibility and survival. One of the immune checkpoint inhibitors is P-selectin glycoprotein ligand-1 (PSGL-1); the majority of tumor-infiltrating leukocytes express PSGL-1, causing T cell and immune inhibition via PSGL-1 mediator molecules. We aimed to investigate the effect of variable number of tandem repeat (VNTR) polymorphism in the second exon of the PSGL-1 gene on MM susceptibility, response to treatment and survival in our patient group. A total of 238 patients diagnosed with MM between January 2010 and January 2021 and 162 healthy individuals as a control group were included in this cross-sectional study. The genotypes of the VNTR polymorphism in the second exon of the PSGL-1 gene were statistically compared between patients and healthy controls; the statistically significant effects of the genotypes on response to first-line treatment and survival were examined. The AC genotype was significantly higher in healthy controls compared to patients diagnosed with MM (p < 0.001). The median PFS in patients with AA/AB/AC was 56 months, while it was 100 months in patients with BB/CC. The hazard ratio of 1.34 for PFS was found to be clinically significant and having the BB/CC genotype could provide a longer PFS compared to others, but it was not statistically significant due to the sample size. Our study results will shed light on new study plans in terms of immune checkpoint target therapies among conventional treatment preferences in MM.
Mitochondria-induced cell death is closely correlated with plant immune responses against pathogens. However, the molecular mechanisms by which pathogens manipulate mitochondria to suppress host resistance remain poorly understood. In this study, a haustorium-specific effector Pst11215 from the wheat stripe rust pathogen Puccinia striiformis f. sp. tritici (Pst) was characterized by host-induced gene silencing. The interaction partners regulated by Pst11215 were screened using the yeast two-hybrid system. In addition, Pst11215-mediated immune regulation modes were further determined. The results showed that Pst11215 was required for Pst virulence. Pst11215 interacted with the wheat voltage-dependent anion channel TaVDAC1, the negative regulator of wheat resistance to stripe rust, in mitochondria. Furthermore, the E3 ubiquitin ligase TaVDIP1 targeted and ubiquitinated TaVDAC1, which can be promoted by Pst11215. TaVDIP1 conferred enhanced wheat susceptibility to Pst by cooperating with TaVDAC1. Overexpression of TaVDIP1 reduced reactive oxygen species (ROS) accumulation and abnormal mitochondria. Our study revealed that Pst11215 functions as an important pathogenicity factor secreted to the host mitochondria to compromise wheat resistance to Pst possibly by facilitating TaVDIP1-mediated ubiquitination of TaVDAC1, thereby protecting mitochondria from ROS-induced impairment. This research unveils a novel regulation mode of effectors hijacking host mitochondria to contribute to pathogen infection.
<P>PROBLEM TO BE SOLVED: To provide at least one double-stranded oligoribonucleotide (dsRNA) designed to inhibit the expression of a target gene.  <P>SOLUTION: One strand of the dsRNA is at least in part complementary to the target gene. The target gene can be selected from the following group: cancer cells, cytokine genes, Id protein genes, developmental genes, and prion genes. The target gene can express in pathogenic organisms (especially Plasmodium). The target gene can preferably also be a part of a virus or viroid which is pathogenic to human.  <P>COPYRIGHT: (C)2008,JPO&INPIT
The clinic of psychological trauma in adolescents still requires further development, whereas it is well documented in adults. This clinic is complex, because it must take into account the nature and type of trauma (recent or not, intentional or not, situations of abuse or sexual violence, etc.), the impact on development, the contexts (social, cultural and family) in which the trauma occurs, and the various vulnerability factors associated with it. This complexity has implications for psychotherapeutic management, which needs to be tailored to the specific clinical profiles of adolescents.

Several studies have evaluated psychotherapy for traumatized adolescents, showing a positive short-term effect on the reduction of post-traumatic stress symptoms, whatever the type of psychotherapy. Few studies, however, have analyzed the therapeutic process and the common factors of change, linked mainly to the therapeutic alliance, the patient's experience and the therapist's role: key factors of change according to the international literature. In this context, the patient's experience of his or her psychotherapeutic follow-up is a source of information that has long been neglected, even though it seems essential for better investigating and understanding the complexity of the processes at play in trauma psychotherapy.
In clinical trials, IARs were reported to occur at any time during and/or within a few hours after the POMBILITI infusion and were more likely to occur with higher infusion rates. IARs were reported in 48 (32%) POMBILITI-treated patients in clinical trials. In these trials, 4 (3%) POMBILITI-treated patients reported 11 severe IARs including symptoms of pharyngeal edema, anaphylactic reaction, urticaria, pruritus, chills, dyspnea, and flushing. The majority of IARs were assessed as mild to moderate. IARs that led to treatment discontinuation were urticaria, anaphylactic reaction, chills, and hypotension.

Antihistamines, antipyretics, and/or corticosteroids can be given prior to POMBILITI administration to reduce the risk of infusion-associated reactions (IARs). However, IARs may still occur in patients after receiving pretreatment.

  


  * If severe IARs occur, immediately discontinue the POMBILITI infusion, initiate appropriate medical treatment, and assess the benefits and risks of readministering POMBILITI following severe IARs. Patients may be rechallenged using slower infusion rates. Once a patient tolerates the infusion, the infusion rate may be increased to reach the recommended infusion rate.
  * If mild or moderate IARs occur regardless of pretreatment, decreasing the infusion rate or temporarily stopping the infusion may ameliorate the symptoms [see Dosage and Administration (2.3)].



Patients with an acute underlying illness at the time of POMBILITI infusion may be at greater risk for IARs. Patients with advanced Pompe disease may have compromised cardiac and respiratory function, which may predispose them to a higher risk of severe complications from IARs.
Carpal tunnel syndrome (CTS) is the most common entrapment neuropathy in the society, which develops due to compression of the median nerve in the carpal tunnel. With the compression of the median nerve, a pain, numbness and tingling sensation spreading to the hand and wrist affects daily living activities and reduces the quality of life. Thickening and myofascial restriction in the carpal tunnel area also contribute to this situation. For this reason, various treatment methods have been developed for CTS, ranging from conservative treatment to surgery. Dry needling is also an alternative treatment method that can be used for CTS. Dry needling allows the fascial tissue to loosen and re-enter the healing process, leading to a decrease in pain and an increase in quality of life. However, its effectiveness in patients with CTS is unknown. This study aimed to examine the effectiveness of dry needling in patients with CTS.
Disclosed are a method and business model for people to inhale hydrogen-containing air or/and oxygen. The method is as follows: at a place of business, an oxygen/hydrogen mixture prepared from electrolyzed water is mixed with air or/and oxygen, and the resulting mixture is then inhaled by people at this place of business or/and is conveyed, through containers or pipelines, away from the place of business for people to inhale. The place of business is a real locale, which may be situated where sales and services are offered and may also be situated at other places for people to spread information. There may be a plurality of places of business, which constitute a chain and/or franchise system. The method, in combination with the Internet, enables data sharing and summarization between the terminals of offline places of business and online e-commerce platforms, so as to realize seamless interfacing and optimal integration. The method can meet the requirement that people readily and safely inhale hydrogen-contained air or/and oxygen.
Participants were required to complete a questionnaire at days 15, 30, 60 and 90 of the study. This questionnaire consisted in asking about having symptoms of SARS-CoV-2 infection, fever, low fever, malaise, headache, loss of smell, runny nose, sore throat.
For all subjects, the IMP was applied 4 times during an intensive dosing regimen for 4 ½-hours (on Day 1 at 0, 1 ½, 3 and 4 ½ - hours). For subjects in Cohort 2 the IMP was likewise applied 4 times during the 4 ½-hour period (on Day 1 at 0, 1 ½, 3 and 4½ hours), but was followed by 2 applications: on Day 1 at 12 hours and on Day 2 at 36 hours.
For 16 weeks, participants will be asked to carry a mobile phone and wear a wrist-worn device for measuring activity. Participants in this arm will receive the psychosocial intervention via a smartphone and context-dependent feedback based on self-report and behavioral data. Providers whose patients are randomized to this arm will also be asked to enroll in order to receive information and notifications about patient status for the duration of the study.
Levofloxacin is an antibacterial agent used for the treatment of many types of infections in adults. This is a randomized, open-label, parallel group, multicenter study to determine the safety and effectiveness of levofloxacin (500 mg by mouth once daily for 7-10 days) compared with another frequently used antibiotic, ciprofloxacin (500 mg by mouth every 12 hours for 7 -10 days), in adults with mild to moderate infections of the skin and the supportive layers beneath the skin. The study consists of 3 visits: one visit \[pre-therapy\] for screening and enrollment, and two visits to assess safety and effectiveness (one visit \[on-therapy\] on Days 3 - 5 of the study and one visit \[post-therapy\] 2 - 7 days after the last dose of the study drug). The total duration of patient participation in the study is approximately 2 weeks. The primary assessments of effectiveness include the clinical response to treatment (defined at post-therapy as cured, improved or failed) and the microbiological response at post-therapy (the rate of eradication of the disease-causing bacteria, determined by patient and by type of bacteria). Safety evaluations (incidence of adverse events, physical examination, physical examination of the skin, and laboratory tests) are performed throughout the study. The study hypothesis is that treatment with levofloxacin is at least as effective and as well tolerated as treatment with ciprofloxacin in patients with mild to moderate infections of the skin and the supportive layers beneath the skin. Levofloxacin 500 mg by mouth once daily, or ciprofloxacin 500 mg by mouth every 12 hours. The duration of treatment is 7 to 10 days.
Amlodipine and losartan are calcium channel and angiotensin II receptor type-1 blockers, respectively, and are established treatments to manage blood pressure (BP) levels for patients with hypertension; both medications are currently marketed in the United States and Europe as anti-hypertensive agents. This is a an open-label, randomized, single dose, three-way crossover study enrolling 24 healthy adult male and female subjects under fasting conditions. Each subject will participate in three treatment periods. The study consists of a screening phase, three treatment periods and a follow-up visit. Subjects will receive each of the following three treatments administered in a randomized three-way crossover design: a reference treatment consisting of a single 5mg amlodipine tablet and a single 100mg losartan tablet; a single fixed dose combination tablet consisting of 5mg amlodipine and 100mg losartan; and another single fixed dose combination tablet consisting of 5mg amlodipine and 100mg losartan; all three treatments will be administered once orally and in a fasted state. Serial blood samples will be obtained at pre-defined timepoints for pharmacokinetic analysis of amlodipine, losartan and carboxylic acid (this is the primary active losartan metabolite). Safety assessments will include measurements of orthostatic vital signs, electrocardiograms (ECG), collection of adverse events (AE) and clinical laboratory tests.
Additional study arm to open based on data collected from Part 2a. Participants with chronic hepatitis B will be administered different doses and frequencies of RO7239958 or placebo SC.